Clario published an article exploring how thoughtful endpoint strategy supports more consistent decision-making across studies in early phase oncology.

Clario, part of Thermo Fisher Scientific, is a leading provider of endpoint data solutions to the life sciences industry. We offer comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Since our founding more than 50 years ago, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported more than 30,000 clinical trial opportunities in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of all FDA drug approvals since 2015. For more information, visit thermofisher.com/clario